L
Laurence Collette
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 281
Citations - 37642
Laurence Collette is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 78, co-authored 276 publications receiving 33811 citations. Previous affiliations of Laurence Collette include VU University Amsterdam & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.
T.H. Van Der Kwast,N. Al Daoud,Laurence Collette,Jenna Sykes,John Thoms,Michael Milosevic,Robert G. Bristow,G. van Tienhoven,Padraig Warde,R.O. Mirimanoff,Michel Bolla +10 more
TL;DR: In this paper, the authors investigated the prognostic significance of intraductal carcinoma of the prostate (IDC-P) in biopsies and transurethral resections prior to external beam radiotherapy with or without androgen deprivation.
Journal ArticleDOI
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay,Sophie Postel-Vinay,Laurence Collette,Xavier Paoletti,Elisa Rizzo,Christophe Massard,Christophe Massard,David Olmos,Camilla Fowst,Bernard Levy,Pierre Mancini,Denis Lacombe,Percy Ivy,Lesley Seymour,Christophe Le Tourneau,Lillian L. Siu,Stan B. Kaye,Jaap Verweij,Jean-Charles Soria,Jean-Charles Soria +19 more
TL;DR: Although protocol-defined DLT period is traditionally limited to C1, almost 20% of patients present significant reductions in RDI at any time in phase 1 trials of MTAs, and recommended phase 2 dose assessment should incorporate all available information from any cycle, and be based on achieving >75% RDI.
Journal ArticleDOI
Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)
Fritz H. Schröder,K. H. Kurth,Sophie D. Fosså,Wytse Hoekstra,Peter P. Karthaus,Linda de Prijck,Laurence Collette +6 more
TL;DR: In this article, the authors evaluated the effect of early versus delayed endocrine treatment in pN1-3 PCa and showed that the difference was not statistically significant, but non-inferiority was also not proved.
Journal ArticleDOI
Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
Laurence Collette,Tomasz Burzykowski,Kevin Carroll,Don Newling,Thomas Morris,Fritz H. Schröder +5 more
TL;DR: The levels of association observed indicate that the effect of hormonal treatment on OS cannot be predicted with a high degree of precision from observed treatment effects on PSA end points, and thus statistical validity is unproven.
Journal ArticleDOI
Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)
Oscar Matzinger,Irma Heimsoth,Philip Poortmans,Laurence Collette,Henk Struikmans,Walter Van den Bogaert,Alain Fourquet,Harry Bartelink,Fatma Ataman,Akos Gulyban,Marianne Pierart,Geertjan van Tienhoven +11 more
TL;DR: IM-MS irradiation seems well tolerated and does not significantly impair WHO PS at three years, suggesting that treatment-related toxicity does not impair patient's daily activities.